Paradigm Shift in Inflammatory Bowel Disease Management: Precision Medicine, Artificial Intelligence, and Emerging Therapies DOI Open Access
Antonio M. Caballero‐Mateos, Guillermo A. Cañadas‐De la Fuente, Beatriz Gros

et al.

Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(5), P. 1536 - 1536

Published: Feb. 25, 2025

Inflammatory bowel disease (IBD) management stands at the cusp of a transformative era, with recent breakthroughs heralding paradigm shift in treatment strategies. Traditionally, IBD therapeutics revolved around immunosuppressants, but landscape has evolved significantly. Recent approvals etrasimod, upadacitinib, mirikizumab, and risankizumab have introduced novel mechanisms action, offering renewed hope for patients. These medications represent departure from status quo, breaking years therapeutic stagnation. Precision medicine, involving Artificial Intelligence, is pivotal aspect this evolution, tailoring treatments based on genetic profiles, characteristics, individual responses. This approach optimizes efficacy, paves way personalized care. Yet, rising cost therapies, notably biologics, poses challenges, impacting healthcare budgets patient access. Ongoing research strives to assess cost-effectiveness, guiding policy decisions ensure equitable access advanced treatments. Looking ahead, future holds great promise. Emerging precision ongoing into targets promise reshape landscape. As these advances continue unfold, patients can anticipate brighter future, one marked by more effective, personalized, accessible

Language: Английский

Paradigm Shift in Inflammatory Bowel Disease Management: Precision Medicine, Artificial Intelligence, and Emerging Therapies DOI Open Access
Antonio M. Caballero‐Mateos, Guillermo A. Cañadas‐De la Fuente, Beatriz Gros

et al.

Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(5), P. 1536 - 1536

Published: Feb. 25, 2025

Inflammatory bowel disease (IBD) management stands at the cusp of a transformative era, with recent breakthroughs heralding paradigm shift in treatment strategies. Traditionally, IBD therapeutics revolved around immunosuppressants, but landscape has evolved significantly. Recent approvals etrasimod, upadacitinib, mirikizumab, and risankizumab have introduced novel mechanisms action, offering renewed hope for patients. These medications represent departure from status quo, breaking years therapeutic stagnation. Precision medicine, involving Artificial Intelligence, is pivotal aspect this evolution, tailoring treatments based on genetic profiles, characteristics, individual responses. This approach optimizes efficacy, paves way personalized care. Yet, rising cost therapies, notably biologics, poses challenges, impacting healthcare budgets patient access. Ongoing research strives to assess cost-effectiveness, guiding policy decisions ensure equitable access advanced treatments. Looking ahead, future holds great promise. Emerging precision ongoing into targets promise reshape landscape. As these advances continue unfold, patients can anticipate brighter future, one marked by more effective, personalized, accessible

Language: Английский

Citations

0